Mar 25 2013
On Friday, March 22 the European Medicines Agency Committee for Medicinal Products for Human Use cleared rivaroxaban (Xarelto) for prevention of atherothrombotic events in patients with acute coronary syndrome. EMA made this decision a few weeks after the US FDA disapproved the drug for the same indication. The news release appears on TheHeart.org.
Comments (0)
Anticoagulant Therapy
No comments here.